EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Blood protein biomarkers in hepatocellular carcinoma: progress and challenges

Lu Zhang, Mingjing Zhang, Yingying Bao, Jiajia Yang, Tingting Luo, Yan Zhang, Yange Wang, Peijie Liu, Xiangqian Guo

PeerJ · 29.04.2026 · 14 · e21196

DOI: 10.7717/peerj.21196 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift PeerJ, online erschienen am 29.04.2026. Verfasst von Lu Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health and Epidemiology, School of Basic Medical Sciences, Henan University, Kaifeng, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Biomarkers, Tumor, Blood Proteins. Die Arbeit nennt 143 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The key scientific research project plan of Henan Province, The program for science and technology development in Henan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC) is an important cause of cancer-related death. Due to the lack of typical clinical symptoms in early-stage HCC, most HCC patients are diagnosed at an advanced stage and have lost the opportunity of surgery, which results in a poor prognosis. Therefore, early detection and timely intervention are the most effective methods to reduce the mortality of HCC. Blood flows through different organs and tissues, and there are abundant tumor biomarkers in blood, which can provide real-time information for the early diagnosis and prognostic prediction of HCC, so blood tumor biomarkers have become an effective supplement to imaging technology. As the most ideal biomarkers for disease diagnosis, serum and plasma proteins have been the main focus for biomarker development. In this review, we summarized the research progress of potential blood protein biomarkers (tumor-associated antigens and tumor-associated autoantibodies) in HCC and discussed their obstacles in clinical translation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsBiomarkers, TumorBlood ProteinsHumansAutoantibodiesPrognosisAntigens, Neoplasm

Stichwörter der Autor:innen

AutoantibodiesBlood proteinHepatocellular carcinomaTumor antigens

Substanzen

Biomarkers, TumorAutoantibodiesAntigens, NeoplasmBlood Proteins

Autor:innen und Institutionen

  • Department of Public Health and Epidemiology, School of Basic Medical Sciences, Henan University, Kaifeng, China.
  • Henan Provincial Engineering Center for Tumor Molecular Medicine, Kaifeng, China.
  • Department of Oncology, Kaifeng Central Hospital, Kaifeng, China.
  • Department of Cell Biology and Genetics, School of Basic Medical Sciences, Henan University, Kaifeng, China.

Förderung

  • The key scientific research project plan of Henan Province
  • The program for science and technology development in Henan Province

Zitieren

APA

Zhang, L., Zhang, M., Bao, Y., Yang, J., Luo, T., Zhang, Y., Wang, Y., Liu, P., & Guo, X. (2026). Blood protein biomarkers in hepatocellular carcinoma: progress and challenges. PeerJ, 14, e21196. https://doi.org/10.7717/peerj.21196

Vancouver

Zhang L, Zhang M, Bao Y, Yang J, Luo T, Zhang Y, et al. Blood protein biomarkers in hepatocellular carcinoma: progress and challenges. PeerJ. 2026;14:e21196. doi:10.7717/peerj.21196

BibTeX
@article{Zhang2026,
  author = {Zhang, Lu and Zhang, Mingjing and Bao, Yingying and Yang, Jiajia and Luo, Tingting and Zhang, Yan and Wang, Yange and Liu, Peijie and Guo, Xiangqian},
  title = {Blood protein biomarkers in hepatocellular carcinoma: progress and challenges},
  journal = {PeerJ},
  year = {2026},
  volume = {14},
  pages = {e21196},
  doi = {10.7717/peerj.21196}
}
Kostenlos starten →